Qiagen N.v. · NYSE:QGEN
Qiagen — Investor Presentation (May 2026)
9 slides from Qiagen's investor presentation, May 7, 2026
Slide 1: QuantiFERON: Driving continuous innovation
SPOTLIGHT QuantiFERON Driving continuous innovation Spotlight Session May 7, 2026
Slide 2: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: Certain statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1
Slide 3: Latent TB market growth led by skin test conversion
Latent TB market growth led by skin test conversion Immunocompromised $1.6 bn annual latent TB market opportunity(1) patients Drug Nursing users homes TB Only ~40% of market converted from skin tests Visitors / outbreaks residents Immigration Students of countries with TB Healthcare Contacts workers
Slide 4: From first-mover to ecosystem leader
From first-mover to ecosystem leader 1st generation 3rd generation NEW QuantiFERON-TB QuantiFERON-TB Breakthrough: New benchmark: New partnerships: New partnership: Blood test to replace Scalable with Workflow standardization Proprietary End-to-End latent TB skin test remote incubation and improved
Slide 5: Creating a complete QuantiFERON ecosystem
Creating a complete QuantiFERON ecosystem 37°C Blood collection Aliquotation Incubation Centrifugation Detection Data analysis Current QuantiFERON workflow Manual intervention steps Announcing a new QuantiFERON ecosystem NEW AI-enabled Fully automated Sample to Insight workflow New chemistry risk st
Slide 6: QuantiFERON differentiates beyond CD4/CD8
Blood collection Aliquotation Incubation Centrifugation Detection Data analysis QuantiFERON differentiates beyond CD4/CD8 CD4/CD8 technology as clinical standard QuantiFERON scales with LIAISON(1) Impaired CD4 responses relevant in some patient groups CLIA II Europe launch in Improved reagent 2025,
Slide 7: Expanded ecosystem enables full automation and improves efficiency
Blood collection Aliquotation Incubation Centrifugation Detection Data analysis Expanded ecosystem enables full automation and improves efficiency Addressing the need to improve pre-analytical steps in labs QIAGEN fully automates the process with Inpeco and Diasorin partnerships Process automation c
Slide 8: AI-enhanced data asset to advance clinical value
Blood collection Aliquotation Incubation Centrifugation Detection Data analysis AI-enhanced data asset to advance clinical value Launch 2027 QuantiFERON AI tool designed to 20+ years create clinical value for physicians Longitudinal TB data and experience, unique to QIAGEN Combines CD4, CD8 Shows ri
Slide 9: QuantiFERON: From test leadership to ecosystem
QuantiFERON: From test leadership to ecosystem 1 Leading latent TB test performance in a growing market Differentiated science and expanded throughput options strengthen QuantiFERON's leadership 2 Advancing workflow automation New Inpeco partnership move QuantiFERON and LIAISON toward a full ecosyst